#1 Clinical Trials Search in Europe

Dexrazoxane Hydrochloride

Dexrazoxane Hydrochloride is being studied in various clinical trials as a protective agent to reduce heart-related side effects of chemotherapy, particularly for patients with blood cancers and breast cancer. It is also being investigated for its potential to prevent tissue damage from accidental extravasation of anthracycline drugs during cancer treatment.

Table of Contents

What is Dexrazoxane Hydrochloride?

Dexrazoxane Hydrochloride is a medication primarily used to protect the heart from the toxic effects of certain chemotherapy drugs. It’s also known by the brand names Zinecard, Totect, and Cardioxane[1][2]. This drug plays a crucial role in making cancer treatments safer for patients by reducing the risk of heart damage.

How Does Dexrazoxane Work?

Dexrazoxane acts as a chemoprotective drug, which means it helps protect normal cells from the side effects of chemotherapy. It works in several ways:

  • It reduces the formation of harmful reactive oxygen species (ROS), which are unstable molecules that can damage heart cells[3].
  • It suppresses a process called apoptosis, which is programmed cell death that can occur in heart cells due to chemotherapy[3].
  • It helps protect the heart by interacting with and modifying the effects of chemotherapy drugs, particularly those in the anthracycline class (like doxorubicin)[4].

What Conditions Does Dexrazoxane Treat?

Dexrazoxane is not a direct treatment for cancer, but it’s used in conjunction with cancer treatments to prevent or reduce heart damage. It’s commonly used in patients receiving:

  • Breast cancer treatment involving anthracycline chemotherapy[4]
  • Treatment for soft tissue sarcomas (cancers that develop in soft tissues like muscles or fat)[5]
  • Chemotherapy for various blood cancers like acute myeloid leukemia, myelodysplastic syndrome, and others[1]
  • Treatment for childhood solid tumors or anaplastic large cell lymphoma[2]

Additionally, dexrazoxane is used to treat accidental extravasation of anthracycline chemotherapy drugs. Extravasation occurs when these drugs leak from the vein into surrounding tissue during intravenous administration, potentially causing severe tissue damage[6][7].

How is Dexrazoxane Administered?

Dexrazoxane is typically given as an intravenous (IV) infusion, which means it’s delivered directly into your vein. The dosage and schedule can vary depending on the specific treatment plan and the chemotherapy drugs being used. Some common administration methods include:

  • Given 15-30 minutes before starting chemotherapy[4]
  • Administered in a specific ratio to the chemotherapy drug (e.g., 10:1 or 15:1 dexrazoxane to chemotherapy drug)[4]
  • Given as a series of doses over consecutive days[1]

Current Clinical Trials

Dexrazoxane is being studied in various clinical trials to expand its use and understand its effects better. Some ongoing research includes:

  • Testing dexrazoxane in children undergoing heart surgery to protect against heart damage during the procedure[3]
  • Investigating the use of dexrazoxane in combination with new cancer treatments to improve their safety[2]
  • Studying the optimal timing and dosing of dexrazoxane to maximize its protective effects[8]

Potential Side Effects

While dexrazoxane is generally well-tolerated, it can have some side effects. These may include:

  • Nausea and vomiting
  • Fatigue
  • Decreased white blood cell count, which could increase the risk of infections
  • Pain or irritation at the injection site

It’s important to note that the benefits of using dexrazoxane to protect your heart often outweigh these potential side effects. Always discuss any concerns with your healthcare provider[1].

Aspect Details
Primary Use Cardioprotective agent during cancer treatment
Cancer Types Studied Blood cancers (AML, MDS, CML), Breast cancer, Soft tissue sarcoma
Administration Intravenous infusion, often before chemotherapy
Key Mechanisms Reduces reactive oxygen species, suppresses cell death, metal chelation
Main Outcomes Measured Changes in heart function (LVEF), cardiac symptoms, troponin levels
Additional Applications Prevention of tissue damage from anthracycline extravasation
Ongoing Research Optimal dosing, long-term effects, impact on cancer treatment efficacy

FAQ

  • What is Dexrazoxane Hydrochloride used for in cancer treatment? Dexrazoxane Hydrochloride is primarily used as a protective agent to reduce heart-related side effects of chemotherapy, especially those caused by anthracycline drugs. It's also being studied to prevent tissue damage from accidental leakage of chemotherapy drugs outside blood vessels.
  • How does Dexrazoxane Hydrochloride work? Dexrazoxane Hydrochloride works by reducing toxic reactive oxygen species and suppressing cell death in heart tissue. It also has metal chelation effects, which may contribute to its protective properties.
  • What types of cancer patients might benefit from Dexrazoxane Hydrochloride? Clinical trials are studying its use in patients with blood cancers like acute myeloid leukemia, myelodysplastic syndrome, and chronic myeloid leukemia, as well as in breast cancer patients receiving anthracycline chemotherapy.
  • Are there any side effects associated with Dexrazoxane Hydrochloride? While Dexrazoxane Hydrochloride is generally used to prevent side effects, it may have its own side effects. These are being closely monitored in clinical trials, with a focus on any potential impact on the effectiveness of cancer treatment.
  • How is Dexrazoxane Hydrochloride administered? In most trials, Dexrazoxane Hydrochloride is given intravenously (through a vein), often before or along with chemotherapy drugs. The exact dosing and schedule can vary depending on the specific trial and treatment regimen.

Ongoing Clinical Trials on Dexrazoxane Hydrochloride

  • Comparison of Cyclophosphamide and Doxorubicin for Treatment of Advanced or Metastatic Soft Tissue Sarcoma in Patients Age 65 and Older

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Anthracycline: A class of chemotherapy drugs used to treat many types of cancer. They can cause heart damage as a side effect.
  • Cardiotoxicity: Damage to the heart muscle caused by certain medications, particularly some cancer treatments.
  • Extravasation: The accidental leakage of medication from a blood vessel into surrounding tissue during intravenous administration.
  • Left Ventricular Ejection Fraction (LVEF): A measurement of how much blood the left ventricle pumps out with each contraction. It's used to assess heart function.
  • Troponin: A protein released into the blood when the heart muscle has been damaged. It's used as a marker for heart injury.
  • Cardiopulmonary bypass: A technique that temporarily takes over the function of the heart and lungs during surgery.
  • Ischemia-reperfusion injury: Tissue damage caused when blood supply returns to tissue after a period of lack of oxygen.
  • Minimal Residual Disease (MRD): Small numbers of cancer cells that remain in the body during or after treatment.
  • Chelation: The process by which a molecule binds and forms a complex with a metal ion.
  • Cardiomyopathy: A group of diseases that affect the heart muscle, making it harder for the heart to pump blood to the rest of the body.

References

  1. https://clinicaltrials.gov/study/NCT03589729
  2. https://clinicaltrials.gov/study/NCT01606878
  3. https://clinicaltrials.gov/study/NCT04997291
  4. https://clinicaltrials.gov/study/NCT00955890
  5. https://clinicaltrials.gov/study/NCT02584309
  6. https://clinicaltrials.gov/study/NCT01596088
  7. https://clinicaltrials.gov/study/NCT00548561
  8. https://clinicaltrials.gov/study/NCT03930680